com701
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 6, 2018 (NCT03667716)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transmembrane protein PVRIGINHIBITOR
PVRIG inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06888921 | Phase 1/Phase 2 (Phase 2) | Jul 21, 2025 | Compugen |
| NCT04570839 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2020 | Bristol-Myers Squibb, Compugen |
| NCT03667716 | Phase 1 | Sep 6, 2018 | Compugen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Compugen | For profit | 3 | 3 | 2 | 2018 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1